PhenomeX Inc. Common Stock
CELL
CELL was delisted on the 29th of September, 2023.
0 hedge funds and large institutions have $0 invested in PhenomeX Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 56 closing their positions.
100% less funds holding
Funds holding: 57 → 0 (-57)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $35.8M → $0 (-$35.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 56
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$9.81M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$4.14M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$3.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.51M |
| 5 |
Swedbank
Stockholm,
Sweden
|
-$2.5M |
CELL Hedge Fund Activity: Q4 2023 in Review
0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in PhenomeX Inc. Common Stock (CELL) for Q4 2023, worth a combined $0 — down 100% from $35.8M a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of CELL and 0 opened new positions — a net loss of 56 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Beryl Capital Management, exiting entirely with an estimated $9.81M sold.
- 0 institutional investors held PhenomeX Inc. Common Stock (CELL) as of Q4 2023, down from 57 in Q3 2023.
- Funds reported $0 of PhenomeX Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new PhenomeX Inc. Common Stock positions in Q4 2023 and 56 closed out, a net change of -56 holders.
- The largest PhenomeX Inc. Common Stock seller in Q4 2023 was Beryl Capital Management, an estimated $9.81M sold.
Based on aggregated 13F filings for Q4 2023.